Title:An Overview of Current Screening and Management Approaches for Prostate Cancer
VOLUME: 16 ISSUE: 8
Author(s):Omar N. Akram, Gohar Mushtaq and Mohammad Amjad Kamal
Affiliation:King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia.
Keywords:Castrate resistant prostate cancer, epidemiology, nano-medicine, nano-technology, prostate cancer, prostate specific antigen, therapy
resistance.
Abstract:Prostate cancer is the fourth leading cause of mortality in Australian men. The prevalence and incidence
is increasing in both developed and developing nations, thus there is a need for better screening and management of
this disorder. While there is no direct known cause of prostate cancer, management is largely focused on early detection
and treatment strategies. Of particular concern is advanced prostate cancer which can manifest as castrate
resistant prostate cancer characterized by therapy resistance. This short review outlines the global epidemiology of
prostate cancer, clinical manifestations, risk factors, current screening strategies including first line clinical screening
as well as the use of circulating biomarkers, and treatment of prostate cancer through mainstream therapeutics as well as the cutting
edge peptide and nano-technology based therapeutics that are being implemented or in the process of development to overcome therapeutic
obstacles in the treatment of prostate cancer.
